US-based NovAccess Global, a biomedical company developing novel immunotherapies for brain tumour patients, has announced a partnership with Thailand-based CKN Ventures, a multifaceted clinical and commercial healthcare platform, to expand clinical data set access in Southeast Asia to enhance and accelerate personalised therapeutics and treatment protocols.

This partnership supports NovAccess Global’s new Precision Medicine Division, launched earlier this month, to develop the most comprehensive collection of personalised therapeutics and treatment protocols using artificial intelligence (AI), Big Data and Predictive technologies.

Using advances in AI, image recognition and predictive data science, NovAccess Global and CKN Ventures will collaborate to expand access to relevant data sources in Asia that will improve the quality and impact of licensed databases to identify patient data (phenotypic, clinical, and genomic) for analysis relating to therapeutic drug development and therapeutic treatment purposes.

Therapeutic and treatment protocol data will be marketed to external pharmaceutical and biotechnology companies, private payers, national/international health agencies and healthcare providers and insurers.

According to Market.us, the global precision medicine market size was $83.4 billion in 2022 and is projected to reach $254 billion by 2032, exhibiting a compounded annual growth rate of 12.1% in the forecast period (2023-2032). Asia is the fastest growing market in the world for the delivery of innovative care in oncology and immune oncology therapeutics, all of which depend upon management of robust, high-quality data sets to discover new treatment pathways.